Amishi Y. Shah

Jan 9, 2025 | nature.com | Pavlos Msaouel |Rahul Sheth |Amishi Y. Shah |Amado J. Zurita |Giannicola Genovese |Minghao Dang | +3 more

AbstractWe conducted a phase I trial to determine the optimal dose of triplet therapy with the tyrosine kinase inhibitor sitravatinib plus nivolumab plus ipilimumab in 22 previously untreated patients with advanced clear cell renal cell carcinoma. The primary endpoint was safety.

Jul 4, 2024 | nature.com | Sang T. Kim |Sattva Neelapu |Amishi Y. Shah |Matthew Campbell |don gibbons |Tina Cascone | +10 more

Correction to: Nature Communications https://doi.org/10.1038/s41467-022-29539-3, published online 12 April 2022In this article the funding information for Jordan Kramer was omitted and should have read, ‘J.K. is supported by the CPRIT Research Training Award CPRIT Training Program (RP210028)’. The original article has been corrected.

May 10, 2023 | nature.com | Jose A. Karam |Pavlos Msaouel |Cara Haymaker |Surena F. Matin |Matthew Campbell |Amado J. Zurita | +4 more

AbstractSitravatinib is an immunomodulatory tyrosine kinase inhibitor that can augment responses when combined with programmed death-1 inhibitors such as nivolumab. We report a single-arm, interventional, phase 2 study of neoadjuvant sitravatinib in combination with nivolumab in patients with locally advanced clear cell renal cell carcinoma (ccRCC) prior to curative nephrectomy (NCT03680521).